Not for release, publication or distribution, directly or indirectly, in or into the United States of America, Australia, Canada or Japan or any other jurisdiction in which such release, publication or distribution would be unlawful. The important notes at the end of this announcement must be observed.

Berlin, October 8, 2025 – The German government today passed a cabinet resolution that includes far-reaching changes to the prescription and distribution of medical cannabis. According to the draft bill, prescriptions will initially only be issued after a personal doctor-patient consultation. For repeat prescriptions, a personal consultation must take place once every four quarters – under this condition, a prescription can also be issued via telemedicine in the following quarters. In addition, medical cannabis flowers may only be sold directly in local pharmacies.

The proposed changes will be discussed in the Bundestag in the next step. Amendments to the law are to be expected in the further parliamentary process. However, if the draft law is passed in its current form, this could at least temporarily weigh on demand for medical cannabis flowers in Germany – especially since many patients currently use telemedicine services for prescriptions.

"The medical use of cannabis is an expression of sustainable development and has already become widely accepted in society. We consider the proposed legal changes to be inappropriate, as they would make access to medical cannabis more difficult, potentially reduce demand for cannabis flowers, at least temporarily, and thus jeopardize a growing industry and jobs in Germany. At Cantourage, we remain committed to providing safe, high-quality, and responsible medical care to patients," says Philip Schetter, CEO of Cantourage.

Cantourage has taken a position on the proposed legislative changes in a statement dated August 1, 2025: Details can be found here.

Cantourage is closely monitoring legislative developments in Germany. The company has been responding to the changing environment for quite some time with a consistent strategy of expansion and diversification.

Cantourage has recently expanded its business activities significantly, particularly in the dynamically growing markets of Poland and the United Kingdom. These international activities not only contribute to further strengthening the company, but also offer additional resilience to possible changes in the German market environment.

At the same time, Cantourage is continuously adapting its product portfolio in Germany to meet changing requirements and continue to ensure the supply of patients. Cantourage thus remains a reliable partner in the field of medical cannabis supply and will continue to respond flexibly and solution-oriented to regulatory changes in the future.

About Cantourage
Cantourage is a leading European company for the production and distribution of medical cannabis. Cantourage enables growers worldwide to sell products in European medical markets. Founded in 2019, the company works with more than 60 cannabis growers from 18 countries. Cantourage ensures the highest pharmaceutical quality standards along the value chain and offers products in all relevant market segments: dried flowers, extracts, dronabinol and cannabidiol. The company has been listed on the Frankfurt Stock Exchange since November 11, 2022, under the ticker symbol “HIGH”.

Contact Investor Relation
ir@cantourage.com

This announcement does not constitute an offer to the public or a solicitation of anoffer to sell securities to the public, in particular not within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

‍